Technical Analysis for RZLT - Rezolute Inc.

Grade Last Price % Change Price Change
C 2.0300 2.53% 0.0500
RZLT closed down 4.58 percent on Thursday, June 8, 2023, on 4 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 2.53%
Bollinger Band Squeeze Range Contraction 2.53%
BB Squeeze + Lower Band Touch Range Contraction 2.53%
Gapped Down Weakness 2.53%
Lower Bollinger Band Touch Weakness 2.53%
20 DMA Resistance Bearish -2.17%
50 DMA Support Bullish -2.17%
Bollinger Band Squeeze Range Contraction -2.17%
Inside Day Range Contraction -2.17%
200 DMA Resistance Bearish -1.46%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 5 hours ago
Up 5% about 8 hours ago
Up 1 ATR about 8 hours ago
200 DMA Resistance about 8 hours ago
50 DMA Resistance about 8 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Rezolute Inc. Description

Rezolute, Inc., a clinical stage biopharmaceutical company, specializes in the development of drug therapies for the treatment of patients with metabolic and orphan diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema; and RZ602, a product candidate that is in preclinical trial for the treatment of hereditary angioedema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. Rezolute, Inc. has a development and license agreement with ActiveSite Pharmaceuticals, Inc. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Louisville, Colorado.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Organ Systems Diabetes Monoclonal Antibodies Stage Biopharmaceutical Recombinant Monoclonal Antibody Insulin Type 2 Diabetes Diabetic Retinopathy Diabetes Mellitus Drug Therapies Orphan Diseases Diabetic Macular Edema Orphan Disease Angioedema Complement Deficiency Hereditary Angioedema Macular Edema Statin Congenital Hyperinsulinism

Is RZLT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.59
52 Week Low 1.34
Average Volume 34,088
200-Day Moving Average 2.1320
50-Day Moving Average 2.0442
20-Day Moving Average 2.0828
10-Day Moving Average 2.0685
Average True Range 0.1508
RSI (14) 44.44
ADX 11.5
+DI 18.2331
-DI 27.2430
Chandelier Exit (Long, 3 ATRs) 1.8476
Chandelier Exit (Short, 3 ATRs) 2.2424
Upper Bollinger Bands 2.1926
Lower Bollinger Band 1.9730
Percent B (%b) 0.03
BandWidth 10.5435
MACD Line -0.0105
MACD Signal Line 0.0008
MACD Histogram -0.0113
Fundamentals Value
Market Cap 16.54 Million
Num Shares 8.35 Million
EPS -0.37
Price-to-Earnings (P/E) Ratio -5.38
Price-to-Sales 0.00
Price-to-Book 38.03
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.1000
Resistance 3 (R3) 2.0967 2.0533 2.0800
Resistance 2 (R2) 2.0533 2.0228 2.0550 2.0733
Resistance 1 (R1) 2.0167 2.0039 1.9950 2.0200 2.0667
Pivot Point 1.9733 1.9733 1.9625 1.9750 1.9733
Support 1 (S1) 1.9367 1.9428 1.9150 1.9400 1.8933
Support 2 (S2) 1.8933 1.9239 1.8950 1.8867
Support 3 (S3) 1.8567 1.8933 1.8800
Support 4 (S4) 1.8600